---
title: "QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence"
description: "Formulary evidence on QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence. Covers SELVA, PALV-06, WMU-NPC-1, TOPICAL, TOPGUN, Topical sirolimus 0.2% single-center interventional study, and 3 further headings. 111 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 SELVA

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Objective: change in disease severity after 24 weeks

> “assess the change in microcystic lymphatic malformations IGA”

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Registry-reported location and actual study dates

| Field | Quoted record |
| --- | --- |
| Country | “United States” |
| Study start | “July 31, 2024” |
| Primary completion | “January 14, 2026” |

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### SELVA: phase 3 study design

> “a Phase 3, single-arm, baseline-controlled trial consisting of an 8-week observational baseline run-in period followed by 24 weeks of active treatment”

Source: [Palvella Therapeutics corporate update and 2026 outlook announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-provides-corporate-update-and-2026-outlook/)

<a id="topic-3.1.1.3-2"></a>

###### SELVA: registry record, identifier and masking

| Information | Source quotation |
| --- | --- |
| Study identifier | “NCT06239480” |
| Masking | “None (Open Label)” |

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### SELVA: registry record, eligibility

| Information | Source quotation |
| --- | --- |
| Inclusion: age | “at least 3 years of age” |
| Inclusion: diagnosis | “clinically confirmed superficial/cutaneous microcystic lymphatic malformation” |
| Exclusion: systemic disease | “severe systemic symptoms that require systemic therapy” |

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Study treatment

> “once-daily QTORIN™ rapamycin”

Source: [Palvella Therapeutics corporate update and 2026 outlook announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-provides-corporate-update-and-2026-outlook/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using mLM-IGA as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Outcome-instrument development

> “The mLM-IGA is a dynamic 7-point change instrument evaluating microcystic LM severity over time”
> “Completed live by the clinician; utilizes pre-treatment photographs”

Source: [Teng et al. (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Novel-Endpoint-Teng.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Clinical-interview support for endpoint selection

> “Physicians unanimously supported the use of a live change scale as the primary endpoint for a Phase 3 clinical trial.”

Source: [Teng et al. (2024)](https://www.palvellatx.com/wp-content/uploads/2024/10/Pedra-2024-Novel-Endpoint-Teng.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### SELVA: registry record, enrollment

| Information | Source quotation |
| --- | --- |
| Enrollment, actual | “51” |

Source: [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment and treatment initiation

| Population | Quoted number |
| --- | --- |
| Original enrollment target | “40” |
| Participants who initiated treatment | “50” |

Source: [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Summary

The primary efficacy population excluded the exploratory participant aged 3 to 5 years. Primary-endpoint missing data were handled by multiple imputation. The reported confirmatory endpoints were evaluated through a prespecified testing hierarchy.

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/); [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### SELVA: efficacy analysis population

> “n=49 subjects aged 6 and older”

Source: [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)

<a id="topic-3.1.1.7.2-3"></a>

###### Missing data and multiplicity control

> “non-completer data handled via multiple imputation per statistical analysis plan for primary endpoint”
> “endpoints tested according to pre-specified hierarchical testing procedure”

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### SELVA: completion of the 24-week efficacy evaluation period

> “44 participants (88%)”

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics of the efficacy population

| Characteristic | Quoted value |
| --- | --- |
| Age in years, mean and range | “19.4 [6-57]” |
| Male-to-female count | “24:25” |
| Prior medical interventions | “34 (69%)” |

Source: [Palvella Therapeutics presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-ex99_1.htm)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### SELVA: primary and key secondary efficacy endpoints

|                                               | “Mean Change at Week 24 (95% CI)” | “p-value” |
| --------------------------------------------- | --------------------------------: | --------: |
| “Primary Endpoint: mLM-IGA*”                  |              “+2.13 (1.88, 2.38)” | “p<0.001” |
| “Key Secondary Endpoint: Blinded mLM-MCSS***” |             “-3.4 (-4.34, -2.38)” | “p<0.001” |

Source: [Treat (2026)](https://www.palvellatx.com/wp-content/uploads/2026/05/ISSVA-QTORIN-Rapamycin-Presentation-by-Dr-Jim-Treat.pdf)

<a id="topic-3.1.1.8.3-2"></a>

###### SELVA: additional clinician-assessed secondary efficacy endpoints

|                 | “Mean Change” | “Two-sided p-value” |
| --------------- | ------------: | ------------------: |
| “Live mLM-MCSS” |        “-4.6” |           “p<0.001” |
| “(CGI-S)”       |        “-1.7” |           “p<0.001” |

Source: [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Blinded mLM-MCSS: observational run-in and treatment periods

| Assessment | Quoted value |
| --- | --- |
| Mean change during the 8-week run-in period | “-0.1” |
| Treatment-period baseline mean score | “9.9” |
| Week-24 mean score | “6.6” |
| Mean change during active treatment | “-3.4” |

Source: [Treat (2026)](https://www.palvellatx.com/wp-content/uploads/2026/05/ISSVA-QTORIN-Rapamycin-Presentation-by-Dr-Jim-Treat.pdf)

Additional sources: [Teng et al. (2025)](https://www.jidonline.org/article/S0022-202X%2825%2900283-0/fulltext)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### SELVA: patient-reported secondary efficacy endpoints

|                 | “Mean Change” | “Two-sided p-value” |
| --------------- | ------------: | ------------------: |
| “(PGI-C)”       |        “+1.9” |           “p<0.001” |
| “(PGI-S)”       |        “-1.0” |           “p<0.001” |

Source: [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm)

<a id="topic-3.1.1.8.4-2"></a>

###### Week-24 treatment satisfaction: overall satisfaction item

> “84% reporting extremely satisfied, very satisfied, or satisfied.”

Source: [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)

<a id="topic-3.1.1.8.4-3"></a>

###### Week-24 treatment satisfaction: participants at least somewhat satisfied

| Assessment | Quoted value |
| --- | --- |
| Proportion | “100%” |
| Respondents | “(43/43)” |

Source: [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### SELVA: safety population

> “n=50 participants in efficacy evaluation evaluated for safety.”

Source: [Palvella Therapeutics presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-ex99_1.htm)

<a id="topic-3.1.1.8.5-2"></a>

###### SELVA: safety

|                                        | “Number of Participants (%)” |
| -------------------------------------- | ---------------------------: |
| “Any Treatment-Emergent Adverse Event” |                   “35 (70%)” |
| “Serious (not related to study drug)”  |                     “4 (8%)” |
| “Any Treatment-Related Adverse Event”  |                   “17 (34%)” |

Source: [Palvella Therapeutics presentation (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526065308/pvla-ex99_1.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### SELVA: treatment-related adverse-event severity

> “all of which were rated mild or moderate.”

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)

<a id="topic-3.1.1.8.5-4"></a>

###### SELVA: most common treatment-related adverse events

> “application site acne, application site discoloration, and application site pruritus (all n=3, 6%).”

Source: [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)

<a id="topic-3.1.1.8.5-5"></a>

###### SELVA: possibly treatment-related discontinuation

> “one participant discontinued due to an adverse event (lymphorrhea) possibly related to study drug.”

Source: [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

SELVA lacked a concurrent placebo or active-treatment comparator. The primary assessment was performed by a clinician in an open-label study; blinded photographic assessment was a separate secondary endpoint. The 24-week efficacy population comprised 49 participants aged at least 6 years, while the exploratory younger cohort contributed only one treated participant. Six of 50 treated participants did not complete the efficacy evaluation period. Baseline-control and imputation methods do not eliminate all risks of expectation bias, confounding, or informative missingness. Treatment satisfaction among completers does not establish an effect on a generic health-utility measure.

Source: [Palvella Therapeutics corporate update and 2026 outlook announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-provides-corporate-update-and-2026-outlook/); [ICH GCP NCT06239480](https://ichgcp.net/clinical-trials-registry/NCT06239480); [Palvella Therapeutics SELVA topline results announcement (2026)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-positive-topline-results-phase-3/); [Palvella Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm); [Palvella Therapeutics Form 10-Q (2026)](https://ir.palvellatx.com/static-files/9b01caef-bc81-4ce3-9481-0e07b6fec802)

Additional sources: [Allemang-Trivalle et al. (2026)](https://www.nature.com/articles/s41598-026-36295-7)

<a id="heading-3.1.2"></a>

#### 3.1.2 PALV-06

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Objective: safety and efficacy of topical QTORIN rapamycin

> “determine the safety and efficacy”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### PALV-06: study setting

> “5 clinical sites in the United States.”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="topic-3.1.2.2-2"></a>

###### Study completion period

> “the 4th quarter of 2022”

Source: [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)

Additional sources: [ClinicalTrials.gov NCT05050149](https://clinicaltrials.gov/study/NCT05050149?aggFilters=status%3Acom&cond=Lymphatic+Abnormalities&rank=3&tab=results)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 2 study design

> “multicenter, baseline-controlled Phase 2 clinical trial.”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### PALV-06: age eligibility

> “Participants were ≥6 years old”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Treatment and duration

> “Participants self-administered topical QTORIN rapamycin once daily for 12 weeks.”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Treatment-Emergent Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Enrolled population

| Population | Quoted number |
| --- | --- |
| Participants enrolled | “12” |

Source: [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Efficacy analysis: nominal significance and paired comparisons

> “no adjustment for multiplicity amongst efficacy endpoints”
> “paired t-tests vs mean change of 0 as compared to baseline”

Source: [Palvella Therapeutics phase 2 topline results announcement (2023)](https://www.biospace.com/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations)

<a id="topic-3.1.2.7.2-2"></a>

###### Formal analysis-set definitions

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### PALV-06: discontinuations

| Information | Source quotation |
| --- | --- |
| Discontinuations | “No study participants discontinued” |

Source: [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### PALV-06: phase 2 efficacy, clinician-reported endpoint

| “Efficacy Endpoints”                            | “Week 12” “Mean” “(n=12)” | “Nominal, Two-sided p-value” |
| ----------------------------------------------- | ------------------------: | ---------------------------: |
| “Clinician Global Impression of Change (CGI-C)” |                    “2.42” |                    “<0.0001” |

Source: [Palvella Therapeutics phase 2 topline results announcement (2023)](https://www.biospace.com/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations)

<a id="topic-3.1.2.8.3-2"></a>

###### Clinician-rated response: much improved or very much improved

> “100% of participants”

Source: [Palvella Therapeutics phase 2 publication announcement (2025)](https://ir.palvellatx.com/news-releases/news-release-details/palvella-therapeutics-announces-publication-results-phase-2)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### PALV-06: phase 2 efficacy, patient-reported endpoint

| “Efficacy Endpoints”                            | “Week 12” “Mean” “(n=12)” | “Nominal, Two-sided p-value” |
| ----------------------------------------------- | ------------------------: | ---------------------------: |
| “Patient Global Impression of Change (PGI-C)”   |                    “2.08” |                    “<0.0001” |

Source: [Palvella Therapeutics phase 2 topline results announcement (2023)](https://www.biospace.com/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations)

<a id="topic-3.1.2.8.4-2"></a>

###### Additional quality-of-life instrument collected

> “dermatology life quality index”

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101)

<a id="topic-3.1.2.8.4-3"></a>

###### Numerical dermatology life quality index results

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### PALV-06: phase 2 safety

| Information | Source quotation |
| --- | --- |
| Serious adverse events | “No serious adverse events” |
| Most common treatment-related adverse events | “application site pain (n=3, 25.0%), application site pruritus (n=3, 25.0%), and nausea (n=2, 16.7%).” |

Source: [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

PALV-06 enrolled 12 participants in an open-label, baseline-controlled study with 12 weeks of treatment. There was no concurrent comparator. Efficacy testing was exploratory, with nominal p-values and no adjustment for multiplicity. The sample size and duration limit assessment of uncommon adverse events and durability after treatment cessation. The abstract identifies a dermatology life quality index assessment but does not provide its numerical results.

Source: [Treat et al. (2024)](https://doi.org/10.1097/jova.0000000000000101); [Palvella Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm); [Palvella Therapeutics phase 2 topline results announcement (2023)](https://www.biospace.com/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-of-qtorin-3-9-percent-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations)

<a id="heading-3.1.3"></a>

#### 3.1.3 WMU-NPC-1

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Efficacy, safety, and concentration selection

> “It aimed to evaluate the efficacy and safety of topical sirolimus gel (NPC-12G) and to estimate the optimal concentration for treatment of cutaneous lesions of VAs.”
> “The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

No evidence found.

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Multicenter randomized parallel-group study

> “double-blind, placebo-controlled, parallel-group”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Age and lesion requirements for entry

> “Patients who are at least 1 month old”
> “patients with target lesions that did not show a tendency to regress within 4 weeks based on interviews and which were visible in photographs”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="topic-3.1.3.4-2"></a>

###### Exclusions for prior mTOR inhibitor and local treatment

> “Patients who had received oral treatment with mTOR inhibitors (sirolimus, everolimus, temsirolimus, etc.) within the 12 weeks prior to registration.”
> “Patients who had received treatment for the target lesion (surgical treatment, endovascular treatment, laser therapy, phototherapy, liquid nitrogen therapy, or elastic bandage) within 3 months prior to registration.”
> “Patients with severe erosions or ulcers on the target lesion.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Alternative sirolimus gel concentrations and treatment schedule

| Field | Quoted value |
| --- | --- |
| Lower active concentration | “0.2%” |
| Higher active concentration | “0.4%” |
| Schedule | “twice per day for 12 weeks.” |

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Photographic Overall Improvement Score as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Independent photographic assessment at week 12

> “overall improvement score”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Enrolled participants by diagnosis

| Diagnosis | Quoted count |
| --- | --- |
| Venous malformation | “27” |
| Lymphatic malformation | “14” |
| Tufted angioma | “8” |
| Kaposiform hemangioendothelioma | “1” |

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Safety, full analysis, and per protocol sets

> “all 50 enrolled subjects were included in the safety analysis set”
> “There were also no case excluded from the full analysis set as there were no violations of eligibility criteria that could have affected efficacy, making the same population as the safety analysis set.”
> “one case in the 0.2% group and two cases in the 0.4% group were excluded from the per protocol set due to low compliance.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Screening, randomization, and dropouts

> “Fifty patients were screened for eligibility, all of whom underwent randomization. After the trial started, three patients dropped out due to low compliance.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: comparisons with placebo

| Active concentration | Quoted p-value |
| --- | --- |
| 0.2% gel | “0.410” |
| 0.4% gel | “0.549” |

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="topic-3.1.3.8.3-2"></a>

###### Primary endpoint: investigator conclusion

> “There was no statistically significant difference in the mean improvement score in the 0.2% group (p = 0.410) or the 0.4% group (p = 0.549) compared with in the placebo group.”
> “Thus, we could not prove the efficacy of topical sirolimus for cutaneous vascular anomalies in this protocol.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="topic-3.1.3.8.3-3"></a>

###### Secondary and post hoc lesion-size findings

> “the improvement in target lesion size at Week 12 assessed by the committee as one of the 16 secondary endpoints was significantly higher in the 0.4% sirolimus gel group than in the placebo group (p = 0.031).”
> “In the post-hoc analysis outside the protocol tracing the contour of the lesion, the percentages of patients with ≥20% reduction in the lesion area increased dose-dependently (0%, 37.5%, and 65.0% in the placebo, 0.2%, and 0.4% group, respectively).”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Application-site adverse events in the 0.4% group

> “irritation and dermatitis”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="topic-3.1.3.8.5-2"></a>

###### Overall safety assessment

> “Regarding safety, irritation and dermatitis at the application site occurred in the 0.4% gel group.”
> “The safety data demonstrated topical sirolimus to have an acceptable safety profile.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

This randomized study evaluated 0.2% and 0.4% topical sirolimus gels, not QTORIN rapamycin 3.9% gel. The diagnostic counts total 50 participants, including 14 with lymphatic malformations. Neither active concentration differed significantly from placebo on the primary photographic improvement endpoint. A lesion-size finding was one of 16 secondary endpoints, and the lesion-area responder analysis was post hoc. The heterogeneous population and different formulations limit application of these results to QTORIN or specifically to microcystic lymphatic malformations.

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="topic-3.1.3.9-2"></a>

###### Investigator-stated limitation and call for confirmatory evidence

> “As a primary endpoint, this trial failed to demonstrate the efficacy of sirolimus gel for VA skin lesions. However, secondary endpoint and post-hoc analyses showed the possibility that sirolimus gel reduced the size of lesions.”
> “To confirm these findings, a precise, long-term, randomized clinical trial with a larger patient group that focuses on lesion size as an endpoint is necessary.”

Source: [Jinnin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40040594/)

<a id="heading-3.1.4"></a>

#### 3.1.4 TOPICAL

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Objective: comparison of topical sirolimus with vehicle

> “The objective is to compare the efficacy and safety of a 12-week application of 0.1% topical sirolimus versus topical vehicle in CMLMs in children and adults.”

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Protocol publication: planned recruitment start

> “This study was due to start recruitment in June 2019 and have a total period of recruitment of 24 months (June 2021).”

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized vehicle-controlled design with matched areas within each participant

> “This French blinded multicenter within-person randomized controlled phase 2 trial aims to include 55 patients aged ≥ 6 years who have a primary CMLM.”

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

Additional sources: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Topical treatment during the blinded comparison period

| Field | Quoted value |
| --- | --- |
| Sirolimus concentration | “0.1%” |
| Application schedule | “once daily for 12 weeks” |

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Physician Global Assessment as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Clinical relevance of change on the primary severity scale

> “a 1-point improvement in PGA score is clinically relevant”

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned enrollment in the published protocol

| Population | Quoted number |
| --- | --- |
| Planned participants | “55” |

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Summary

The protocol specifies paired Student t tests for the within-participant severity comparison and multiple imputation for missing primary outcomes.

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

No evidence found.

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The retrieved publication is a protocol rather than a results report. It describes a matched-area, vehicle-controlled comparison during the first 12 weeks, followed by treatment of the whole malformation. The within-person design depends on the comparability of lesion areas and avoidance of treatment contamination between areas. The authors note that systemic absorption could reduce differences between treated and control areas. This 0.1% cream protocol does not establish the efficacy or safety of QTORIN rapamycin 3.9% gel.

Source: [Leducq et al. (2019)](https://link.springer.com/article/10.1186/s13063-019-3767-8)

<a id="heading-3.1.5"></a>

#### 3.1.5 TOPGUN

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

Additional sources: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study setting

> “3 French hospital centers”

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized timing of treatment introduction

| Field | Quoted value |
| --- | --- |
| Allocation ratio across four sequences | “1:1:1:1” |

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

Additional sources: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Once-daily local administration to the lingual malformation

| Field | Quoted value |
| --- | --- |
| Sirolimus solution strength | “1-mg/mL” |
| Smaller target-area dose | “0.5 mL” |
| Larger target-area dose | “1 mL” |

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Physician Global Assessment as the Primary Endpoint

Additional sources: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Sample-size rationale in the protocol

> “we did not perform any sample size calculation.”

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Summary

The planned mixed-effects linear model includes a participant-specific random intercept for repeated severity measurements. Missing observations are not imputed.

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="topic-3.1.5.7.2-2"></a>

###### Missing-data handling

> “Missing data will not be imputed”

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

Additional sources: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The publication reports a stepped-wedge protocol, not final efficacy or safety results. There is no placebo intervention. Participants and investigators know when treatment starts, although the photographic adjudication committee is blinded. No formal sample-size calculation was performed. The analysis plan models repeated severity measurements, but does not impute missing observations. Local application of a 1 mg/mL oral solution to lingual lesions is not equivalent to cutaneous QTORIN rapamycin 3.9% gel.

Source: [Marchand et al. (2022)](https://link.springer.com/article/10.1186/s13063-022-06365-y)

<a id="heading-3.1.6"></a>

#### 3.1.6 Topical sirolimus 0.2% single-center interventional study

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

No evidence found.

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

No evidence found.

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

No evidence found.

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

No evidence found.

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using an Unreported Outcome Measure as the Primary Endpoint

No evidence found.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

Additional sources: [Xu et al. (2026)](https://www.dovepress.com/short-term-efficacy-and-safety-of-topical-sirolimus-gel-in-pediatric-s-peer-reviewed-fulltext-article-VHRM)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

No evidence found.

<a id="heading-3.1.7"></a>

#### 3.1.7 SIR-DA-0901

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

Additional sources: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Recruitment interval

| Field | Quoted value |
| --- | --- |
| Recruitment began | “October 2009” |
| Recruitment ended | “April 2013” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

Additional sources: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

Additional sources: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Oral sirolimus dosing and target exposure

| Field | Quoted value |
| --- | --- |
| Starting dose per administration, mg/m² | “0.8” |
| Target trough concentration, ng/mL | “10 to 15” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Composite Functional, Quality-of-life, and Radiologic Response as the Primary Endpoint

Additional sources: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Enrolled and evaluable populations

| Population | Quoted number |
| --- | --- |
| Enrolled | “Sixty-one” |
| Evaluable at course 6 | “57” |
| Evaluable at course 12 | “53” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Two-stage response assessment

> “Simon’s optimal 2-stage design”

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Discontinuations for persistent adverse effects

| Outcome | Quoted count |
| --- | --- |
| Participants taken off study medication | “Two” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Baseline age and updated diagnostic classification

| Characteristic | Quoted value |
| --- | --- |
| Median age in years | “8.1” |
| Participants classified as having microcystic lymphatic malformations | “5” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Response at the end of course 6

| Response | Quoted count |
| --- | --- |
| Partial response | “47” |
| Stable disease | “3” |
| Progressive disease | “7” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Sirolimus-attributable toxicities of grade 3 or higher

| Toxicity category | Quoted proportion |
| --- | --- |
| Blood or bone marrow | “27%” |
| Gastrointestinal | “3%” |
| Metabolic or laboratory | “3%” |

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

This phase 2 trial studied systemic oral sirolimus, not a topical formulation. It enrolled a heterogeneous population of complicated vascular anomalies without a concurrent comparator. The article reclassified the original diagnostic categories, leaving five participants classified as having microcystic lymphatic malformations. Outcomes from the overall population therefore cannot be treated as a microcystic-specific response estimate. The composite response definition incorporates functional and quality-of-life changes as well as imaging, so a partial response is not equivalent to radiographic lesion resolution.

Source: [Adams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4732362/)

<a id="heading-3.1.8"></a>

#### 3.1.8 PERFORMUS

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Efficacy, safety, and delineation of treatment indications

> “To assess the efficacy and safety of sirolimus for children with slow-flow vascular malformations to better delineate the indications for treatment.”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Recruitment interval

| Field | Quoted date |
| --- | --- |
| First recruitment date | “September 28, 2015” |
| Last recruitment date | “March 22, 2018” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Observational-phase randomized design with randomized switch time

> “This multicenter, open-label, observational-phase randomized clinical trial included 59 children aged 6 to 18 years with a slow-flow vascular malformation who were recruited between September 28, 2015, and March 22, 2018, in 11 French tertiary hospital centers.”
> “Participants first underwent an observational period (OP) with no treatment and then switched to an interventional period (IP) when they received sirolimus. The switch time was randomized from month 4 to month 8, and the whole study period lasted 12 months for each patient”
> “The trial was an open-label trial. However, the primary outcome was based on an objective outcome (ie, MRI scans interpreted by a radiologist blinded to treatment periods).”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Age, malformation type, and exclusions

> “Criteria for eligibility were pediatric patients, aged 6 to 18 years, with a complicated slow-flow vascular malformation (VM, LM apart from pure macrocystic LM, and combined venolymphatic malformations, including syndromic forms) extending to underlying tissues (subcutaneous tissue and muscles), confirmed by magnetic resonance imaging (MRI).”
> “We did not include children younger than 6 years of age because MRI requires sedation for children of this age.”
> “We excluded children with a vascular malformation that required immediate medical treatment or individuals who had contraindications to MRI or sirolimus (allergy, immunosuppression, chronic infectious disease or cancer, liver insufficiency, cytopenia, hypercholesterolemia, pregnancy, and women of childbearing age not using birth control).”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Systemic treatment exposure target

| Field | Quoted value |
| --- | --- |
| Sirolimus target serum concentration, ng/mL | “4-12” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Change in Malformation Volume on Magnetic Resonance Imaging as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Centralized blinded imaging as the objective measure

> “The primary outcome was change in the volume of vascular malformations detected on magnetic resonance imaging scan (with centralized interpretation) per unit of time (ie, between the interventional period and the observational period).”
> “The MRI scans were centralized and interpreted by the same radiologist (B.M.), with blinding to participants’ names and protocol sequence time.”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Enrollment and main analysis population

| Population | Quoted count |
| --- | --- |
| Enrolled | “63” |
| Main analysis | “59” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Missing-data handling for the primary analysis

> “multiple imputations”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

###### Treatment discontinuation because of adverse events

| Outcome | Quoted count |
| --- | --- |
| Participants discontinuing treatment | “5” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Baseline malformation categories

| Category | Quoted count |
| --- | --- |
| Pure venous malformations | “22” |
| Lymphatic malformations | “18” |
| Combined malformations | “19” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Primary volumetric comparison: overall population

> “not overall significantly different”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="topic-3.1.8.8.3-2"></a>

###### Primary volumetric comparison: by malformation subtype

> “Variations in the volume of vascular malformations detected on magnetic resonance imaging scans associated with the duration period were not overall significantly different between the interventional period and the observational period (all vascular malformations: mean [SD] difference, –0.001 [0.007]; venous malformations: mean [SD] difference, 0.001 [0.004]; combined malformations: mean [SD] difference, 0.001 [0.009]).”
> “However, a significant decrease in volume was observed for children with pure lymphatic malformations (mean [SD] difference, –0.005 [0.005]).”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="topic-3.1.8.8.3-3"></a>

###### Investigator conclusion on the best indication for systemic sirolimus

> “Pure lymphatic malformations seem to be the best indication for sirolimus therapy because evidence of decreasing lymphatic malformation volume per unit of time, oozing, and bleeding and increasing quality of life was found.”
> “In combined malformations, sirolimus significantly reduced pain, oozing, and bleeding. Benefits seemed lower for pure venous malformations than for the 2 other subgroups, also based on symptoms.”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="topic-3.1.8.8.3-4"></a>

###### Systemic sirolimus: absence of complete regression

> “In no case was complete regression observed.”

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.8.8.4-1"></a>

###### Children with no quality-of-life impairment on the dermatology instrument

| Assessment | Quoted proportion |
| --- | --- |
| Baseline | “27.1%” |
| Month 12 | “54.2%” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Safety during the sirolimus intervention period

| Outcome | Quoted value |
| --- | --- |
| Participants with adverse events | “56” |
| Adverse events | “231” |
| Serious adverse events | “5” |
| Oral-ulcer proportion | “49.2%” |

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

PERFORMUS included children aged 6 to 18 years and did not study QTORIN. Treatment was open label, although imaging was assessed by a blinded radiologist. The primary analysis did not show an overall effect on malformation-volume change; a reduction was reported for the lymphatic subgroup. Subgroup results should not be substituted for an overall positive primary result. The authors identify inability to control for time as a confounder in the primary analysis because imaging was available at only three time points.

Source: [Maruani et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8444064/)

<a id="heading-3.1.9"></a>

#### 3.1.9 VASE

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

Additional sources: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Trial initiation

> “The trial was registered at ClinicalTrials.gov (NCT02638389) and EudraCT (2015-001703-32) and started in January 2016.”

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Study design

> “nonrandomized prospective trial”

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

Additional sources: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Systemic sirolimus treatment

| Field | Quoted value |
| --- | --- |
| Starting dose in children younger than 12 years, mg/m² twice daily | “0.8” |
| Starting dose in older participants | “2 mg/day” |
| Planned treatment duration | “2 years” |

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Patient-reported Symptoms and Functional Limitation as the Primary Endpoint

Additional sources: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Planned enrollment and interim evaluation

| Population | Quoted number |
| --- | --- |
| Planned full-trial enrollment | “250” |
| Interim population | “132” |

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

<a id="topic-3.1.9.7.2-1"></a>

###### Interim statistical approach

> “descriptive statistics”

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

<a id="topic-3.1.9.8.1-1"></a>

###### Completion of the planned 2-year treatment period in the interim report

| Outcome | Quoted count |
| --- | --- |
| Participants completing treatment | “61” |

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Age strata in the interim population

| Stratum | Quoted count |
| --- | --- |
| Pediatric participants | “31” |
| Adult participants | “101” |

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Systemic sirolimus: clinical improvement in the interim population

> “a clinical improvement in 85% of patients”

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="topic-3.1.9.8.3-2"></a>

###### Post-trial personalized-regimen cohort

> “Thirty adults were included”

Source: [Seront et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04151-y)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Grade 3 or 4 adverse events in the interim report

| Outcome | Quoted value |
| --- | --- |
| Participants | “24” |
| Proportion | “18%” |

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095)

<a id="topic-3.1.9.8.5-2"></a>

###### Adverse-event rates after switching to personalized intermittent or on-demand regimens

> “AEs decreased from 73–85% during continuous therapy to 9–33% with intermittent/on-demand regimens, with no reported grade ≥3 event.”

Source: [Seront et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04151-y)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

VASE was nonrandomized and included heterogeneous slow-flow vascular malformations. Its interim symptom and safety analysis did not establish a QTORIN-specific or microcystic-specific effect. The authors identify limited pediatric enrollment, small diagnostic subgroups, and limited genetic characterization. The later personalized-regimen analysis included 30 selected adults who had previously completed two years of sirolimus and experienced recurrent symptoms. Its retrospective design and selection of prior responders limit causal comparison of dosing schedules and extrapolation to children or treatment-naive participants.

Source: [Seront et al. (2023)](https://insight.jci.org/articles/view/173095); [Seront et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04151-y)

## Related pages
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations.md)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic information and modeling report](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: prevalence by geography](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses.md)
